People with multiple sclerosis (MS) who switch between more than two disease-modifying therapies (DMTs) have a higher risk of relapses compared with those who never switch, regardless of how well these patients adhere to their prescribed medications, according to real-world study in Canada.
According to the researchers, these findings are consistent with a greater number of treatment switches in individuals with a poor response to different therapies and/or higher disease activity.
However, among patients who ever switched treatments, those who changed to second-line DMTs had a 56% lower risk of relapse after the switch compared with those who remained on a first-line DMT. That result suggests that higher-efficacy therapies can more effectively control relapses in these patients.
Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified.
